Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Steatosis~* ALT \>1.5 times normal~* ALT/AST ratio \>1.0~* Normal Kidney Function~Exclusion Criteria:~* Normal ALT within last 6 months~* Advanced fibrosis based on 1) biopsy, if available (Stage 3 or 4 NAFLD), 2) imaging, or 3) lab (platelet count \<150,000)~* Daily alcohol use above 20 g/day for women and 30 g/day for men~* Prescription use of ursodiol, ezetimibe, vitamin E, fish oils, thiazolidinediones, insulin, sulfonylureas, HMG-CoA reductase inhibitors~* Weight loss greater than 15% in past 12 months~* Pregnant or breastfeeding~* Body Mass index greater than 50~* Largest body circumference greater than 160 cm~* Claustrophobia~* Allergy to ezetimibe or ursodiol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EZ-URSO Combination Therapy (Type: EXPERIMENTAL): Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).